The White House review of drug prices: Don't hate the player — hate the game
Foreign nations are sponging off American investment into pharmaceutical R&D and taking advantage of by US patients by systematically underpaying for drugs, a new study by the White House has concluded.
Surging drug prices in the United States are a thorny yet rare bipartisan issue as another presidential election beckons. While President Trump struggles to make good on his promise to lower drug prices, the biopharma industry, which has long thrived in its laissez-faire ecosystem, has persistently argued that government intervention will stifle innovation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.